1,219 results on '"Marquez, Victor E."'
Search Results
2. Structure-Activity Relationships (SAR)
3. Cytidine Deaminase
4. Bicyclo[3.1.0]Hexane Nucleosides
5. The AIDS Era
6. Zebularine as an Epigenetic Anticancer Agent
7. Diacylglycerol Lactones and Protein Kinase C (PKC)
8. 3-Deazaneplanocin A and Cyclopentenylcytosine
9. Epigenetics and Cancer
10. Brain Antitumor Agents
11. Privileged Drug Scaffolds
12. Exploration of Novel Nucleoside Templates in Search of Active Anti-HIV and Antiviral Drugs
13. Tiazofurin and the History of Thiazole-4-Carboxamide Adenide Dinucleotide (TAD)
14. 3-Deazaneplanocin A (DZNep) as an Epigenetic Anticancer Agent
15. Changes in DNA Bending Induced by Restricting Nucleotide Ring Pucker Studied by Weak Alignment NMR Spectroscopy
16. Fourier Transform Ion Cyclotron Resonance MS Reveals the Presence of a Water Molecule in an Enzyme Transition-State Analogue Complex
17. Activation of Munc13-1 by Diacylglycerol (DAG)-Lactones
18. β 2-Chimaerin Is a Novel Target for Diacylglycerol: Binding Properties and Changes in Subcellular Localization Mediated by Ligand Binding to Its C1 Domain
19. Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas
20. Data from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
21. Supplementary Table 2 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
22. Data from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
23. Supplementary Figure 2 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
24. Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
25. Data from Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
26. Supplementary Figures 1-4 from Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
27. Supplementary Table 7 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
28. Supplementary Figure Legend from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
29. Supplementary Table 5 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
30. Supplementary Table 1 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
31. Supplementary Table 3 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
32. Perspective from Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
33. Supplementary Table 4 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
34. Supplementary Table 6 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
35. Supplementary Figure 2 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
36. Supplementary Figures 1 - 5 from Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
37. Supplementary Table 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
38. Supplementary Table 1 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
39. Supplementary Figure 3 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
40. Supplementary Figure 4 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
41. Supplementary Figure 2 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
42. Supplementary Table 2 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
43. Supplementary Materials and Methods from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
44. Supplementary Fig. S3B from DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
45. Data from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
46. Supplementary Figure 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
47. Supplementary Figure and Table Legends 1-4 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
48. Supplementary Figure 1 from Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
49. Supplementary Figure 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
50. Supplementary Figure Legend from Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.